Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
See termination reason in detailed description.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive estrogen receptor positive early breast cancer , who are disease-free after completion of 2 to 3 years of tamoxifen and continue the treatment with Aromasin® until completion of 5 years of adjuvant hormonal therapy, to understand how Aromasin® is used in routine clinical practice, to assess adherence to prescribed Aromasin® treatment and to understand reasons for its early discontinuation.
The study prematurely discontinued on October 11, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aromasin | Drug | Aromasin® one 25 mg tablet to be taken once daily |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness (to study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. | Baseline up to Month 36 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Concomitant Morbidities | Participants who had a concomitant morbidity during the study for any period of time; participants with more than one concomitant morbidity were counted for each of the concomitant morbidity classes applicable. | Baseline up to Month 36 |
| Number of Participants With Concomitant Medications |
Not provided
Inclusion Criteria:
Postmenopausal females, defined as one from the next :
Patients who have had surgical treatment for histologically confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Patients who are disease-free after 2 to 3 years of adjuvant tamoxifen treatment.
Patients whose tumour was estrogen receptor positive (ER+).
Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Estrogen receptor positive early breast cancer patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| General Hospital Karlovac | Karlovac | 47000 | Croatia | |||
| University Hospital Center Osijek |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Exemestane | Participants received exemestane (Aromasin) in accordance with Summary of Product Characteristics (SmPC) and adjusted according to medical and therapeutic necessity in a sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin) up to 5 years or until tumor relapse occurred. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Exemestane | Participants received exemestane (Aromasin) in accordance with Summary of Product Characteristics (SmPC) and adjusted according to medical and therapeutic necessity in a sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin) up to 5 years or until tumor relapse occurred. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Adverse Events (AEs) | Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness (to study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. | Safety analysis set included participants who received at least one dose of the study medication during the observation period. | Posted | Number | participants | Baseline up to Month 36 |
|
Not provided
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Exemestane | Participants received exemestane (Aromasin) in accordance with Summary of Product Characteristics (SmPC) and adjusted according to medical and therapeutic necessity in a sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin) up to 5 years or until tumor relapse occurred. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (14.1) | Non-systematic Assessment |
The study was prematurely discontinued, therefore not all data was analyzed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C056516 | exemestane |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Concomitant medication (any medication other than, and in addition to, the study medication) taken for any period of time during the study and was coded by World Health Organization (WHO) medical dictionary. |
| Baseline up to Month 36 |
| Percentage of Participants Who Discontinued the Study Medication | Baseline up to Month 36 |
| Number of Participants With Reasons for Discontinuation From Study Medication | Baseline up to Month 36 |
| Time to Discontinuation | Baseline up to Month 36 |
| Recurrence-free Survival | Recurrence-free survival defined as the time from the initiation of study medication to the date of confirmation of any recurrence - as local or distant breast cancer recurrence; new primary breast cancer (ipsilateral or contralateral), death due to any cause. | Baseline up to Month 36 |
| Overall Survival | Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). | Baseline until death (up to Month 36) |
| Osijek |
| 31000 |
| Croatia |
| General Hospital Pula | Pula | 52000 | Croatia |
| University Hospital Center Rijeka | Rijeka | 51000 | Croatia |
| University Hospital Center Split | Split | 21000 | Croatia |
| General Hospital Varazdin | Varaždin | 42000 | Croatia |
| Clinic for Tumors | Zagreb | 10000 | Croatia |
| University Hospital Center "Sestre milosrdnice" | Zagreb | 10000 | Croatia |
| North Estonia Medical Centre Foundation | Tallinn | 13419 | Estonia |
| Institute for Oncology and Radiology of Serbia | Belgrade | 11000 | Serbia |
| Oncology Clinic, Medical center, Bezanijska Kosa | Belgrade | 11080 | Serbia |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Type of Tumor | Number of participants with different types of tumor such as; ductal carcinoma, lobular carcinoma, invasive ductal carcinoma, invasive lobular carcinoma, papillary carcinoma, medullary carcinoma, mucinous (colloid) carcinoma and others. | Number | participants |
|
| Type of Surgery | Number of participants who had undergone different type of surgeries which included mastectomy, axilla evacuation, breast quadrantectomy, dissectio axillae, radical mastectomy, axillary dissection, ablation of both breast, segmentectomy, lymphadenectomy, lumpectomy, core biopsy, sentinel lymph node biopsy, quadrantectomy, re-excision, tumorectomy. | Number | participants |
|
| Hormone Receptor Status | Number of participants with positive estrogen receptors. | Number | participants |
|
| Lymph Node Status | Number | participants |
|
| Tumor Node Metastasis (TNM) Stage | TNM:based on tumor size, if cancer cells had spread to nearby lymph nodes (LN), or distant (other parts of body) metastasis. Stages included:stage 0(no evidence of cancer cells), stage 1(T1N0M0), stage IIA(T0N1M0, T1N1M0, T2N0M0), stage IIB(T2N1M0, T3N0M0), stage IIIA(T0N2M0, T1N2M0, T2N3M0, T3N1orN2M0), stage IIIb( T4 anyNM0, any TN3M0),stage IIIC(any TN3M0), stage IV(anyT anyNM1), where T0=early form of tumor, T1=<2 centimeter(cm), T2=2-5 cm, T3=>2 cm, T4=large sized, N0=not spread to LN, N1=spread to 1 to 3,N2=spread to 4 to 9,N3=spread >10 axillary LN, M0=no metastasis, M1= Metastasis. | Number | participants |
|
| Histopathological Grade | The grade of a cancer depends on what the cells look like and the growth-rate. Lower grade indicates a slower-growing cancer and a higher grade indicates a faster-growing one. Grade 1 (resemble normal cells, not growing rapidly), grade 2 (grow faster than normal cells), grade 3 and 4 (abnormal cells, grow and spread aggressively). | Number | participants |
|
| Number of participants on chemotherapy | Number of participants who received chemotherapy. Chemotherapeutic drugs included doxorubicin, cyclophosphamide, docetaxel, fluorouracil, methotrexate , 5-fluorouracil, epirubicin, endoxan, farmorubicin, adriamycin, cytoxan, trastuzumab. | Number | participants |
|
| Number of participants on radiotherapy | Number of participants who received radiotherapy as measured in radiations per centigray (Rads/cGy). | Number | participants |
|
| Concomitant morbidities in the past | Participants who had a concomitant morbidity in the past; participants with more than one concomitant morbidity were counted for each of the concomitant morbidity classes applicable. | Number | participants |
|
|
|
| Secondary | Number of Participants With Concomitant Morbidities | Participants who had a concomitant morbidity during the study for any period of time; participants with more than one concomitant morbidity were counted for each of the concomitant morbidity classes applicable. | Safety analysis set included participants who received at least one dose of the study medication during the observation period. | Posted | Number | participants | Baseline up to Month 36 |
|
|
|
| Secondary | Number of Participants With Concomitant Medications | Concomitant medication (any medication other than, and in addition to, the study medication) taken for any period of time during the study and was coded by World Health Organization (WHO) medical dictionary. | Safety analysis set included participants who received at least one dose of the study medication during the observation period. | Posted | Number | participants | Baseline up to Month 36 |
|
|
|
| Secondary | Percentage of Participants Who Discontinued the Study Medication | Data was not analyzed as the study was terminated due to insufficient number of participants enrolled in the study. | Posted | Baseline up to Month 36 |
|
|
| Secondary | Number of Participants With Reasons for Discontinuation From Study Medication | Data was not analyzed as the study was terminated due to insufficient number of participants enrolled in the study. | Posted | Baseline up to Month 36 |
|
|
| Secondary | Time to Discontinuation | Data was not analyzed as the study was terminated due to insufficient number of participants enrolled in the study. | Posted | Baseline up to Month 36 |
|
|
| Secondary | Recurrence-free Survival | Recurrence-free survival defined as the time from the initiation of study medication to the date of confirmation of any recurrence - as local or distant breast cancer recurrence; new primary breast cancer (ipsilateral or contralateral), death due to any cause. | Data was not analyzed as the study was terminated due to insufficient number of participants enrolled in the study. | Posted | Baseline up to Month 36 |
|
|
| Secondary | Overall Survival | Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). | Data was not analyzed as the study was terminated due to insufficient number of participants enrolled in the study. | Posted | Baseline until death (up to Month 36) |
|
|
| 0 |
| 46 |
| 2 |
| 46 |
| Hot flush | Vascular disorders | MedDRA (14.1) | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D017437 |
| Skin and Connective Tissue Diseases |
| Title | Measurements |
|---|---|
|
| Crohn's disease |
|
| Fatigue |
|
| Multiple allergies |
|
| Skin infection |
|
| Diabetes mellitus |
|
| Arthralgia |
|
| Collagen disorder |
|
| Intervertebral disc protrusion |
|
| Osteoporosis |
|
| Headache |
|
| Depression |
|
| Hypertension |
|